Tarsus Pharmaceuticals, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed March 14, 2022. Tarsus is a development-stage biopharmaceutical company with no approved products and no product-sale revenue.
Business context and pipeline
The company’s lead candidate, TP-03 (lotilaner eye drops), was in Phase 3 development for Demodex blepharitis. Saturn-1 met its primary and secondary endpoints; Saturn-2 completed enrollment of 412 patients in February 2022, with topline results expected in April 2022. If positive, Tarsus expected to submit an NDA in 2022. Other programs include TP-03 for meibomian gland disease (Phase 2a planned for 1H 2022), TP-04 for rosacea (Phase 2 planned for 2H 2022), and TP-05 for Lyme disease prophylaxis and possible malaria transmission reduction (Phase 1 underway).
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| License fees and collaboration revenue | $57.0 million | $0 |
| Research and development expense | $41.7 million | $18.8 million |
| General and administrative expense | $25.4 million | $8.2 million |
| Operating loss | $12.2 million | $27.0 million |
| Net loss | $13.8 million | $26.8 million |
| Net loss per share, basic and diluted | $0.67 | $4.32 |
| Operating cash flow | $3.7 million provided | $21.1 million used |
Revenue arose from the China out-license with LianBio, not product sales: $53.1 million in license fees and $4.0 million in collaboration revenue. The $57.0 million revenue less $2.1 million in related costs yielded an approximate 96% contribution before R&D, G&A, and other expenses; the company nevertheless recorded a net loss. FY2021 operating cash flow benefited from $55 million of cash receipts from LianBio.
At year-end, cash and cash equivalents were $171.3 million, marketable securities $0.5 million, total assets $178.9 million, and total liabilities $12.2 million. The filing reported no credit-facility borrowing at December 31, 2021. In February 2022, Tarsus entered a facility of up to $175 million and drew $20 million; further tranches are conditional. Management estimated available resources, including expected China payments and facility availability, would fund planned operations into the second half of 2024, subject to assumptions and milestones.
Material changes versus FY2020
- Revenue increased from zero to $57.0 million, primarily reflecting the LianBio China agreement and related development milestones.
- Net loss narrowed by $13.0 million, while R&D and G&A expenses rose substantially as clinical development and company expansion advanced.
- Operating cash flow improved from $21.1 million used to $3.7 million provided, mainly due to China-license receipts; this should not be viewed as recurring product cash generation.
- Cash and cash equivalents increased by $3.2 million. Stock-based compensation increased to $8.5 million from $0.8 million.
Outlook, risks, and unusual items
- Management expected further increases in development and commercialization-readiness spending, and anticipated continued operating losses. Profitability depends on clinical success, approval, launch, market adoption, reimbursement, and additional financing.
- Key near-term catalysts were Saturn-2 results and a potential 2022 NDA submission. These were expectations, not guarantees; approval remained subject to FDA review and possible additional studies.
- The LianBio agreement provided $55 million cash in 2021, with additional payments contingent on clinical, regulatory, supply, and sales milestones, plus tiered mid-to-high-teen royalties. The agreement covers China, Hong Kong, Macau, and Taiwan and may be terminated by LianBio on 90 days’ notice.
- The February 2022 credit facility has staged availability and restrictive covenants; repayment is secured by substantially all assets, with a negative pledge on intellectual property. The reported cash runway depends partly on future conditional funding and milestone receipts.
- Major risks include dependence on TP-03, clinical and regulatory uncertainty, uncertain market-size and adoption estimates, reliance on Elanco-licensed IP and third-party manufacturing, and potential COVID-19 disruption. Tarsus also noted FDA-recommended carcinogenicity testing and embryofetal studies in a second species for TP-03.
- The 2021 results include fair-value losses of $0.6 million on LianBio shares and $1.0 million on LianBio warrants. The independent auditor issued an unmodified opinion; management reported effective disclosure controls and internal control over financial reporting.
Most important facts for investors to verify
- Saturn-2 final efficacy and safety results, and whether the FDA accepts the planned evidence and NDA timing.
- Actual timing and receipt of the expected LianBio milestones, and the conditions and availability of undrawn credit tranches.
- Cash burn and expense growth as Tarsus prepares for potential commercialization and advances other candidates.
- Manufacturing readiness, supplier diversification, and any additional FDA-required studies or formulation work.
- Whether management’s market-size, diagnosis, pricing, reimbursement, and adoption assumptions prove supportable.